Medtronic plc MDT NYSE

Medtronic plc (MDT) generated $7.04B in operating cash flow for fiscal year 2025. After capital expenditures of $1.86B, free cash flow was $5.19B.

Free cash flow margin was 15.5% of revenue. Cash conversion ratio was 1.5x, indicating earnings are backed by cash.

The company returned $3.59B in dividends and $3.24B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (86/100, Pass) — $5.19B (15.5% FCF margin) supports a durable competitive advantage
• INCOME (55/100) — Cash conversion ratio was 1.5x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 69/100 with 3/7 criteria passed.